Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running
September 13, 2018 05:00 ET
|
F. Hoffmann-La Roche Ltd
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Sustainability is an integral part...
Roche zum zehnten Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet
September 13, 2018 05:00 ET
|
F. Hoffmann-La Roche Ltd
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Nachhaltigkeit ist ein...
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
September 06, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
New and updated pivotal data from the TECENTRIQ lung programme, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage...
Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
August 30, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a...
Changes to the Roche Corporate Executive Committee
August 28, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 28 August 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to...
Änderungen in der Konzernleitung von Roche
August 28, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 28. August 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass Roland Diggelmann, CEO der Division Diagnostics und Mitglied der Konzernleitung, Roche per 30. September 2018...
Changes to the Roche Corporate Executive Committee
August 28, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 28 August 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to...
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
August 20, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval follows priority review of Alecensa in China, just eight and nine months after EMA and FDA approvals, respectively Supporting data showed Alecensa significantly reduced the risk of...
FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies
August 13, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies As many as 15 million Americans have food allergies - including approximately 6 million...
TEST -- Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
August 05, 2018 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel 16 April 2018 Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability...